Abstract:The programmed cell death 1 (PD-1) signaling pathway, a key player in immune checkpoint regulation, has become a focal point in cancer immunotherapy. In the context of cancer, upregulated PD-L1 on tumor cells can result in T cell exhaustion and immune evasion, fostering tumor progression. The advent of PD-1/PD-L1 inhibitor has demonstrated clinical success by unleashing T cells from exhaustion. Nevertheless, challenges such as resistance and adverse effects have spurred the exploration of innovative strategies, with bispecific antibodies (BsAbs) emerging as a promising frontier. BsAbs offer a multifaceted approach to cancer immunotherapy by simultaneously targeting PD-L1 and other immune regulatory molecules. We focus on recent advancements in PD-1/PD-L1 therapy with a particular emphasis on the development and potential of BsAbs, especially in the context of solid tumors. Various BsAb products targeting PD-1 signaling are discussed, highlighting their unique mechanisms of action and therapeutic potential. Noteworthy examples include anti-TGFβ × PD-L1, anti-CD47 × PD-L1, anti-VEGF × PD-L1, anti-4-1BB × PD-L1, anti-LAG-3 × PD-L1, and anti-PD-1 × CTLA-4 BsAbs. Besides, we summarize ongoing clinical studies evaluating the efficacy and safety of these innovative BsAb agents. By unraveling the intricacies of the tumor microenvironment and harnessing the synergistic effects of anti-PD-1/PD-L1 BsAbs, there exists the potential to elevate the precision and efficacy of cancer immunotherapy, ultimately enabling the development of personalized treatment strategies tailored to individual patient profiles.

Recent advances and challenges of bispecific antibodies in solid tumors

Current landscape and future directions of bispecific antibodies in cancer immunotherapy

Bispecific Antibody Treatment of Multiple Myeloma: Latest Updates from the 2022 ASH Annual Meeting

Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies

Immunotherapeutic progress and application of bispecific antibody in cancer

The present and future of bispecific antibodies for cancer therapy

Current status and future perspectives of bispecific antibodies in the treatment of lung cancer

Bispecific antibodies: advancing precision oncology

Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors

Advances in the study of CD47‐based bispecific antibody in cancer immunotherapy

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling

State-of-the-Art Approaches to Heterologous Expression of Bispecific Antibodies Targeting Solid Tumors

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy

Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison

Clinical efficacy and safety of bispecific antibodies for the treatment of solid tumors: a systematic review and meta-analysis

Bispecific Antibodies: From Research to Clinical Application

Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects

Therapeutic Bispecific Antibodies Against Intracellular Tumor Antigens